Continuing Education Course #2: Current Understanding of Hemostasis

Toxicologic Pathology

Volumn 39, Issue 1, 2011, Pages 273-280

  Gale, Andrew J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

coagulation; hemophilia; hemostasis; platelets; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ANIMAL; BLEEDING; BLOOD CLOTTING DISORDER; CONTINUING EDUCATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; PATHOLOGY; REVIEW; THROMBOCYTE; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; EDUCATION, CONTINUING; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTASIS; HUMANS; THROMBOSIS;

EID: 79959501463     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310389474     Document Type: Review

References (70)

1. Bauer K. A. (2000). Hypercoagulable states. In Hematology Basic Principles and Practice (Hoffman R. Benz E. J. Shattil S. J. Furie B. Silberstein L. E. McGlave P., eds.), 3rd ed., pp. 2009–39. Churchill Livingstone, New York.
2. Bauer K. A. (2001). Fondaparinux sodium: A selective inhibitor of factor Xa. Am J Health Syst Pharm 58 Suppl 2, S14–S17.
3. Bennett J. S. (2000). Hereditary disorders of platelet function. In Hematology Basic Principles and Practice (Hoffman R. Benz E. J. Shattil S. J. Furie B. Silberstein L. E. McGlave P., eds.), 3rd ed., pp. 2154–72. Churchill Livingstone, New York.
4. Bouma B. N. von dem Borne P. A. Meijers J. C. (1998). Factor XI and protection of the fibrin clot against lysis—a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 80, 24–27.
5. Brass L. F. (2000). The molecular basis for platelet activation. In Hematology Basic Principles and Practice (Hoffman R. Benz E. J. Shattil S. J. Furie B. Silberstein L. E. McGlave and P., eds.), 3rd ed., pp. 1753–70. Churchill Livingstone, New York.
6. Broze G. J. Jr. Warren L. A. Novotny W. F. Higuchi D. A. Girard J. J. Miletich J. P. (1988). The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 71, 335–43.
7. Burch J. W. Stanford N. Majerus P. W. (1978). Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61, 314–19.
8. Cohen M. (2009). Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheter Cardiovasc Interv 74, 579–97.
9. Cramer T. J. Griffin J. H. Gale A. J. (2010). Factor V Is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Pathophysiol Haemost Thromb 37, 17–23.
10. Dahlback B. (2000). Blood coagulation. Lancet 355, 1627–32.
11. Damus P. S. Hicks M. Rosenberg R. D. (1973). Anticoagulant action of heparin. Nature 246, 355–57.
12. Egeberg O. (1965). Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 13, 516–30.
13. Emsley J. Knight C. G. Farndale R. W. Barnes M. J. Liddington R. C. (2000). Structural basis of collagen recognition by integrin alpha2beta1. Cell 101, 47–56.
14. Esmon C. T. Owen W. G. (1981). Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78, 2249–52.
15. Falati S. Gross P. Merrill-Skoloff G. Furie B. C. Furie B. (2002). Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 8, 1175–81.
16. Federici A. B. (2008). Prophylaxis of bleeding episodes in patients with von Willebrand’s disease. Blood Transfus 6 Suppl 2, s26–s32.
17. Franchini M. Mannucci P. M. (2008). Venous and arterial thrombosis: Different sides of the same coin? Eur J Intern Med 19, 476–81.
18. Fulcher C. A. Gardiner J. E. Griffin J. H. Zimmerman T. S. (1984). Proteolytic inactivation of activated human factor VIII procoagulant protein by activated protein C and its analogy to factor V. Blood 63, 486–89.
19. Furie B. (2009). Pathogenesis of thrombosis. Hematology Am Soc Hematol Educ Program 255–58.
20. Furie B. Furie B. C. (1990). Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 75, 1753–62.
21. Giossi A. Pezzini A. Del Z. E. Volonghi I. Costa P. Ferrari D. Padovani A. (2010). Advances in antiplatelet therapy for stroke prevention: The new P2Y12 antagonists. Curr Drug Targets 11, 380–91.
22. Guinto E. R. Esmon C. T. (1984). Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. J Biol Chem 259, 13986–92.
23. Hagen I. Nurden A. Bjerrum O. J. Solum N. O. Caen J. (1980). Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann’s thrombasthenia and Bernard-Soulier syndrome. J Clin Invest 65, 722–31.
24. Han X. Fiehler R. Broze G. J. Jr. (2000). Characterization of the protein Z-dependent protease inhibitor. Blood 96, 3049–55.
25. Hanasaki K. Arita H. (1988). Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists. Biochem Pharmacol 37, 3923–29.
26. Harenberg J. (2009). Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 102, 811–15.
27. Hoffman M. Monroe D. M. III. (2001). A cell-based model of hemostasis. Thromb Haemost 85, 958–65.
28. Jackson S. P. (2007). The growing complexity of platelet aggregation. Blood 109, 5087–95.
29. James K. Taylor F. B. Jr. Fudenberg H. H. (1967). The effect of alpha-2-macroglobulin in human serum on trypsin, plasmin, and thrombin activities. Biochim Biophys Acta 133, 374–76.
30. Kahn M. L. Zheng Y. W. Huang W. Bigornia V. Zeng D. Moff S. Farese R. V. Jr. Tam C. Coughlin S. R. (1998). A dual thrombin receptor system for platelet activation. Nature 394, 690–94.
31. Kehrel B. Wierwille S. Clemetson K. J. Anders O. Steiner M. Knight C. G. Farndale R. W. Okuma M. Barnes M. J. (1998). Glycoprotein VI is a major collagen receptor for platelet activation: It recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood 91, 491–99.
32. Kirchhofer D. Nemerson Y. (1996). Initiation of blood coagulation: The tissue factor/factor VIIa complex. Curr Opin Biotechnol 7, 386–91.
33. Lam S. C. Plow E. F. D’Souza S. E. Cheresh D. A. Frelinger A. L. III Ginsberg M. H. (1989). Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem 264, 3742–49.
34. Lane D. A. Philippou H. Huntington J. A. (2005). Directing thrombin. Blood 106, 2605–2612.
35. Laux V. Perzborn E. Heitmeier S. von D. G. Dittrich-Wengenroth E. Buchmuller A. Gerdes C. Misselwitz F. (2009). Direct inhibitors of coagulation proteins—the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 102, 892–99.
36. Lijnen H. R. Collen D. (2000). Molecular and cellular basis of fibrinolysis. In Hematology Basic Principles and Practice (Hoffman R. Benz E. J. Shattil S. J. Furie B. Silberstein L. E. McGlave and P., eds.), 3rd ed., pp. 1804–14. Churchill Livingstone, New York.
37. Luo B. H. Springer T. A. (2006). Integrin structures and conformational signaling. Curr Opin Cell Biol 18, 579–86.
38. Mann K. G. Nesheim M. E. Church W. R. Haley P. Krishnaswamy S. (1990). Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 76, 1–16.
39. Mannucci P. M. (2008). Back to the future: A recent history of haemophilia treatment. Haemophilia 14 Suppl 3, 10–18.
40. Mannucci P. M. Tuddenham E. G. (2001). The hemophilias—from royal genes to gene therapy. N Engl J Med 344, 1773–79.
41. Marlar R. A. Griffin J. H. (1980). Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest 66, 1186–89.
42. Mills D. C. (1996). ADP receptors on platelets. Thromb Haemost 76, 835–56.
43. Mills D. C. Puri R. Hu C. J. Minniti C. Grana G. Freedman M. D. Colman R. F. Colman R. W. (1992). Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 12, 430–36.
44. Nieswandt B. Brakebusch C. Bergmeier W. Schulte V. Bouvard D. Mokhtari-Nejad R. Lindhout T. Heemskerk J. W. Zirngibl H. Fassler R. (2001). Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 20, 2120–30.
45. Phillips D. R. Agin P. P. (1977). Platelet membrane defects in Glanzmann’s thrombasthenia. Evidence for decreased amounts of two major glycoproteins, J Clin Invest 60, 535–45.
46. Pipe S. W. (2008). Recombinant clotting factors. Thromb Haemost 99, 840–50.
47. Quinsey N. S. Greedy A. L. Bottomley S. P. Whisstock J. C. Pike R. N. (2004). Antithrombin: In control of coagulation. Int J Biochem Cell Biol 36, 386–89.
48. Rau J. C. Beaulieu L. M. Huntington J. A. Church F. C. (2007). Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 5 Suppl 1, 102–15.
49. Rodeghiero F. Castaman G. Tosetto A. (2009). How I treat von Willebrand disease. Blood 114, 1158–65.
50. Ruggeri Z. M. (2007). The role of von Willebrand factor in thrombus formation. Thromb Res 120 Suppl 1, S5–S9.
51. Ruggeri Z. M. Mendolicchio G. L. (2007). Adhesion mechanisms in platelet function. Circ Res 100, 1673–85.
52. Schulze H. Shivdasani R. A. (2005). Mechanisms of thrombopoiesis. J Thromb Haemost 3, 1717–24.
53. Shen L. Dahlback B. (1994). Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 269, 18735–38.
54. Shimada K. Kobayashi M. Kimura S. Nishinaga M. Takeuchi K. Ozawa T. (1991). Anticoagulant heparin-like glycosaminoglycans on endothelial cell surface. Jpn Circ J 55, 1016–21.
55. Siedlecki C. A. Lestini B. J. Kottke-Marchant K. K. Eppell S. J. Wilson D. L. Marchant R. E. (1996). Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 88, 2939–50.
56. Sonnenberg A. Modderman P. W. Hogervorst F. (1988). Laminin receptor on platelets is the integrin VLA-6. Nature 336, 487–89.
57. Sugidachi A. Asai F. Yoneda K. Iwamura R. Ogawa T. Otsuguro K. Koike H. (2001). Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol 132, 47–54.
58. Suzuki K. Nishioka J. Hashimoto S. (1983). Protein C inhibitor: Purification from human plasma and characterization. J Biol Chem 258, 163–68.
59. Tangelder G. J. Slaaf D. W. Arts T. Reneman R. S. (1988). Wall shear rate in arterioles in vivo: least estimates from platelet velocity profiles. Am J Physiol 254, H1059–64.
60. Terraube V. O’Donnell J. S. Jenkins P. V. (2009). Factor VIII and von Willebrand factor interaction: Biological, clinical and therapeutic importance. Haemophilia 16, 3–13.
61. Tollefsen D. M. Majerus D. W. Blank M. K. (1982). Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 257, 2162–69.
62. Varga-Szabo D. Pleines I. Nieswandt B. (2008). Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 28, 403–12.
63. Vu T. K. Hung D. T. Wheaton V. I. Coughlin S. R. (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64, 1057–68.
64. Walker F. J. (1980). Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 255, 5521–24.
65. Weber R. Weimar C. Diener H. C. (2009). Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke. Expert Opin Pharmacother 10, 1883–94.
66. Weitz J. I. (1997). Low-molecular-weight heparins. N Engl J Med 337, 688–98.
67. Wuillemin W. A. Minnema M. Meijers J. C. Roem D. Eerenberg A. J. Nuijens J. H. ten Cate H. Hack C. E. (1995). Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 85, 1517–26.
68. Xiao T. Takagi J. Coller B. S. Wang J. H. Springer T. A. (2004). Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 432, 59–67.
69. Yago T. Lou J. Wu T. Yang J. Miner J. J. Coburn L. Lopez J. A. Cruz M. A. Dong J. F. McIntire L. V. McEver R. P. Zhu C. (2008). Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest 118, 3195–3207.
70. Zucker-Franklin D. (2000). Megakaryocyte and platelet structure. In Hematology Basic Principles and Practice (Hoffman R. Benz E. J. Shattil S. J. Furie B. Silberstein L. E. McGlave and P., eds.), 3rd ed., pp. 1730–40. Churchill Livingstone, New York.